SURMOUNT-1 Trial: Tirzepatide Weight Loss Results, Design, and How It Compares to STEP

Tirzepatide is not the same molecule as semaglutide. It is a single peptide that activates two different receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) act on the GLP-1 receptor only. Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes glycemic control; the molecule, dose range, and injection device are the same across both brand names, but the FDA-approved indications differ.

What SURMOUNT-1 actually tested

SURMOUNT-1 was a 72-week, randomized, double-blind, placebo-controlled trial in 2,539 adults with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. Participants were assigned 1:1:1:1 to tirzepatide 5 mg, 10 mg, 15 mg, or placebo, all starting at a 2.5 mg dose and escalating by 2.5 mg every four weeks until reaching the assigned maintenance dose. Everyone, including the placebo group, received lifestyle counseling on diet and physical activity. The trial was published in the New England Journal of Medicine in 2022. Mean baseline weight was approximately 105 kg and mean BMI was about 38.

Tirzepatide 15 mg produced a mean reported weight loss of roughly 20.9% of body weight at 72 weeks versus roughly 3.1% with placebo in adults with obesity but without type 2 diabetes, and about 57% of patients on that dose lost 20% or more of their starting weight. That is the core, quotable result of SURMOUNT-1. The boundary matters as much as the number: this is a single manufacturer-sponsored trial in a non-diabetic population followed for 72 weeks, not a lifetime outcome, and not a head-to-head comparison against any other drug.

Reported mean weight loss by dose at 72 weeks:

• Tirzepatide 5 mg: approximately 15.0%
• Tirzepatide 10 mg: approximately 19.5%
• Tirzepatide 15 mg: approximately 20.9%
• Placebo: approximately 3.1%

All three doses were reported as statistically superior to placebo. Secondary measures, including waist circumference, fasting insulin, triglycerides, systolic blood pressure, and HbA1c, reportedly improved across the active-treatment arms. Readers and editors should confirm the exact percentages and confidence intervals against the original NEJM publication before they are presented to patients as precise figures; this draft treats them as well-established directionally but recommends verification of decimal-level precision.

Gastrointestinal adverse events, mainly nausea, diarrhea, vomiting, and constipation, were the most common reason for stopping the drug. Discontinuation due to GI events was reported in roughly the mid-single digits to low double digits of participants depending on dose, clearly higher than placebo. Serious adverse events occurred at similar rates across active and placebo arms. The current Zepbound prescribing label is the authoritative source for the complete, updated safety profile, including boxed warnings and contraindications, and should be checked directly rather than relied on from this summary. (FDA Zepbound label)

How SURMOUNT-1 compares to the semaglutide STEP trials

The question most clinicians and patients actually want answered is how a roughly 21% weight-loss result stacks up against semaglutide 2.4 mg (Wegovy), the other major GLP-1-class option for obesity. The semaglutide STEP program included several separate trials, each answering a different question, and none of them enrolled the same participants as SURMOUNT-1.

STEP-1 enrolled a similar population, adults with obesity or overweight and a comorbidity, without type 2 diabetes, and followed them for 68 weeks. It reported mean weight loss of approximately 14.9% with semaglutide 2.4 mg versus approximately 2.4% with placebo. Because STEP-1 and SURMOUNT-1 used similar entry criteria, they are the two trials most often placed side by side. They were not run against each other, they differed slightly in duration (68 versus 72 weeks) and dose-escalation schedule, and the study populations were not identical. A difference of roughly 6 percentage points in mean weight loss between the two trials is a reasonable description of the gap, but it should be described as a cross-trial comparison, not a proven superiority claim.

STEP-2 tested semaglutide in adults who did have type 2 diabetes, and reported a smaller mean weight loss, around 9.6% with the 2.4 mg dose versus roughly 3.4% with placebo. Weight loss is consistently smaller in trials that enroll people with type 2 diabetes, across both the STEP and SURMOUNT programs, likely reflecting differences in appetite-hormone physiology and concurrent glucose-lowering therapy. The tirzepatide equivalent, SURMOUNT-2, enrolled adults with type 2 diabetes and reported higher weight loss than STEP-2 at the top tirzepatide dose, though the exact figures should be checked against the primary publication before being quoted precisely.

STEP-3 added semaglutide to an intensive behavioral therapy program including a structured low-calorie diet phase, and reported a larger effect than STEP-1's standard lifestyle counseling arm, supporting the idea that drug and behavioral treatment add together rather than substitute for each other. SURMOUNT-3 used an analogous design for tirzepatide, with a lifestyle run-in phase before randomization, and reported further weight loss from randomization on top of the run-in loss.

STEP-5 followed semaglutide participants for 104 weeks (two years) and reported that weight loss largely plateaued after roughly 60 weeks and was maintained through two years on continuous treatment. SURMOUNT-4 tested the tirzepatide equivalent of this durability question directly, using a lead-in phase followed by randomization to continued drug or placebo, and it is one of the more clinically important results in either program.

What happens when the drug is stopped

SURMOUNT-4 is the trial that answers a question patients frequently ask before starting: what happens if treatment stops. Participants first completed an open-label tirzepatide lead-in period and lost substantial weight, then were randomized to continue tirzepatide or switch to placebo. Those who continued tirzepatide lost additional weight; those switched to placebo regained a meaningful portion of what they had lost within about a year. The semaglutide STEP program has reported a similar regain pattern after discontinuation in its own withdrawal analyses. Together, these findings are consistent with how obesity medicine organizations, including the American Association of Clinical Endocrinologists, describe obesity as a chronic condition that generally requires ongoing treatment rather than a fixed course, similar to how blood pressure or cholesterol medications are managed. This is a guideline framing, not a guarantee for any individual patient, and some patients maintain weight after stopping through sustained lifestyle change alone; the trial data describe the average, not every person.

Cardiovascular outcomes: an important asymmetry

Semaglutide 2.4 mg has a completed dedicated cardiovascular outcomes trial in adults with established cardiovascular disease and obesity but without type 2 diabetes, which reported a reduction in major adverse cardiovascular events versus placebo, published in the New England Journal of Medicine in 2023. Tirzepatide does not yet have a completed, published cardiovascular outcomes trial in the equivalent population; a dedicated trial has been running and its results were not available at the time of this review. This is a genuine, current asymmetry between the two drugs' evidence bases, not a matter of relative weight-loss magnitude, and it should be disclosed to patients who are choosing between the two options primarily for cardiovascular risk reduction rather than weight loss alone. This status is time-sensitive and should be re-checked against clinicaltrials.gov and each drug's current FDA label before publication.

What about older adults?

Most of the headline SURMOUNT-1 and STEP figures come from trial populations that were not specifically enrolled for age extremes. A post hoc analysis of the SURMOUNT and SUMMIT trial data specifically examined tirzepatide's effects in adults aged 65 and older (pubmed.ncbi.nlm.nih.gov/42303274). Specific efficacy and safety figures for that subgroup should be pulled from that publication directly rather than assumed to mirror the overall trial population, since older adults carry different risks around lean mass loss, frailty, and polypharmacy. Separately, researchers have begun exploring data-driven approaches to identifying which patients are most likely to benefit from weight-loss drug therapy (pubmed.ncbi.nlm.nih.gov/42062622), which is a useful signal that individualized prioritization, rather than a single weight-loss percentage, is where this field is heading.

Evidence boundary: what is established, what is not

Established from published randomized trials: tirzepatide 5, 10, and 15 mg each produced statistically significant, substantially larger weight loss than placebo in a non-diabetic obesity population over roughly a year and a half. Semaglutide 2.4 mg produced statistically significant weight loss versus placebo across several trial populations, including with and without type 2 diabetes, with and without intensive behavioral support. Gastrointestinal side effects are the dominant tolerability issue for both drugs, and stopping either drug is associated with meaningful weight regain within about a year for most patients who lose weight on it.

Plausible but not proven by direct comparison: that tirzepatide produces greater weight loss than semaglutide 2.4 mg in a matched, randomized, head-to-head obesity population. No such trial has been completed and published as of this review. The tirzepatide-versus-semaglutide head-to-head trial that does exist (SURPASS-2) was conducted in adults with type 2 diabetes using semaglutide 1 mg, not the 2.4 mg obesity dose, so it cannot be used to settle the weight-loss-only question.

Not established: whether tirzepatide reduces major cardiovascular events to a similar or different degree than semaglutide has been shown to. Long-term safety and efficacy beyond roughly two years for either drug. Optimal duration of treatment, and whether any subgroup of patients can safely discontinue without substantial regain.

A framework for weighing tirzepatide against semaglutide trial evidence

This is not a dosing tool and does not replace individualized clinical judgment. It organizes the tradeoffs that the trial evidence above actually supports, for a clinician or patient trying to decide what matters most in their own case.

The practical takeaway: the honest comparison between these two drug classes is not "which one wins" but "which tradeoffs match this patient's clinical picture and access constraints," since the two have never been tested against each other in the population most readers are asking about.

Practical points on dosing, monitoring, and lean mass

The SURMOUNT-1 escalation schedule mirrors the Zepbound label: starting at 2.5 mg weekly and increasing by 2.5 mg roughly every four weeks toward a maintenance dose of 5, 10, or 15 mg, with slower titration allowed for patients who do not tolerate a scheduled increase. This is general labeled dosing information, not an individualized prescription, and any specific titration decision should be made with the prescribing clinician.

Monitoring during escalation typically includes weight checks, blood pressure, and glucose or HbA1c in patients at risk for glycemic changes. Patients should be told that weight loss commonly slows or plateaus in the second half of the first year of treatment at a given dose, and that this plateau reflects physiological adaptation rather than a sign the drug has stopped working.

A portion of weight lost on GLP-1-class and GIP/GLP-1 drugs is lean mass rather than fat mass; body-composition sub-studies have reported roughly one-third of total weight lost as lean mass in some analyses. Resistance training during treatment is a reasonable, low-risk way to reduce that fraction, though no randomized trial has defined an optimal protocol specific to tirzepatide.

When to seek urgent care

Severe abdominal pain that does not resolve, especially with vomiting, could indicate pancreatitis and needs prompt medical evaluation rather than waiting for a scheduled visit. Signs of a serious allergic reaction, signs of gallbladder disease (right upper abdominal pain, jaundice), or a lump or swelling in the neck along with hoarseness or trouble swallowing (given the labeled thyroid C-cell tumor signal seen in rodent studies) also warrant contacting a clinician promptly rather than self-managing.